ECPM and Pharsight Announce Distribution Agreement.

MOUNTAIN VIEW, Calif.--(BW HealthWire)--July 6, 1999--

Agreement Provides Multimedia Training System on Clinical Pharmacology

For Pharmaceutical, Biotechnology and Health Sciences Industries

The European Center of Pharmaceutical Medicine (ECPM) and Pharsight Corporation today announced a distribution agreement for ECPM's RIDO(TM) ("Right Dose First Time") training system on clinical pharmacology and drug development simulation. Under this agreement, Pharsight will have nonexclusive rights to distribute the RIDO trainer in North America and Japan.

RIDO is an interactive, multimedia training program that helps teach the basics of clinical pharmacology and the impact that trial simulation can have on improving the efficiency of clinical drug development. RIDO was created by the ECPM, with support from the Community Programme for Education and Training in Technology (COMETT) of the European Union, through a collaboration of scientists from ECPM, University Hospital Basel, University of Auckland, the United States Food and Drug Administration, Hoffmann-La Roche Ltd., and Novartis Ltd. The ECPM also distributes the RIDO PLUS(TM), containing a combination of the RIDO trainer and a clinical trial simulation tool for interactive instruction in trial design principles.

This distribution agreement extends the relationship between Pharsight and the ECPM. Pharsight's computer-assisted trial design solution, the Pharsight(R) Trial Designer, was designed under an alliance with the ECPM, resulting in the incorporation of ECPM's simulation technology into the Pharsight product. This earlier agreement gave Pharsight the exclusive worldwide rights to modify and commercialize the modified RIDO clinical trial simulator. ECPM has also cooperated with Pharsight on the transfer of the clinical trial design technology and the education of the clinical development community.

"We look forward to continuing our work with Pharsight and expect that the RIDO clinical pharmacology trainer will help Pharsight's customers increase the awareness of clinical pharmacology issues among their clinical development staff," says Professor Fritz Buhler, director of the ECPM and the University of Basel.

"Pharsight is dedicated to creating comprehensive and fully integrated pharmaceutical software solutions," says Art Reidel, co-founder, president and CEO of Pharsight Corporation. "RIDO will help us in that mission, providing a multimedia training tool on clinical pharmacology fundamentals."

Utilizing Pharsight's software, clinical drug development teams implement more efficient and cost-effective drug trials, significantly reducing the time to market for important new drugs. Pharsight's Trial Designer and WinNonlin(TM) products allow clinical researchers to model and simulate decisions ranging from initial drug dosing to the design of complete clinical trials, gaining knowledge of drug characteristics and the range of likely trial outcomes. Pharsight's products are in use by thousands of clinical researchers and scientists at 18 of the top 20 pharmaceutical companies worldwide.

PHARSIGHT CORPORATION

Pharsight Corporation is the leading developer and marketer of software products and consulting services that help significantly reduce the complexity, cost and duration of the clinical development process. The company's proprietary technology and world-class consulting expertise enable pharmaceutical and biotechnology companies to make more confident decisions in dealing with complex issues of drug development and product portfolio management. Thus Pharsight helps companies derive greater shareholder value by enabling them to make more informed and objective decisions that lead to more successful and predictable trial outcomes. Pharsight's integrated suite of computer-assisted clinical trial design, modeling, forecasting and simulation products are standards in the industry, and are used by the top pharmaceutical companies and many of the leading biotechnology companies. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight Corporation is available on the Worldwide Web at http://www.pharsight.com.

ECPM

European Center of Pharmaceutical Medicine (ECPM) is a virtual University Institute with an international inter-faculty collaborative network under the auspices of the European Confederation of the Upper Rhine Universities Basel, Freiburg i.Br. and Strasbourg partnering with various Health Care players to address aspects of Pharmaceutical Medicine and Drug Development Science. ECPM is based in the University Hospital of the University of Basel, in Basel, Switzerland. Information about the ECPM is available on the worldwide web at http://www.ecpm.ch.

Note to Editors: Pharsight's Trial Designer is a registered trademark and WinNonlin is a trademark of Pharsight Corporation. RIDO is a trademark of the ECPM. Other product and service names mentioned are the property of their respective owners.